Jump to content


Pfizer announces FDA acceptance of new drug application for bosutinib for patients with previously treated ph chronic myeloid leukemia

  • Please log in to reply
1 reply to this topic

#1 mikefromillinois


    Advanced Member

  • Members
  • PipPipPip
  • 93 posts

Posted 27 January 2012 - 10:26 AM

8:02 AM ET 1/27/12 | Briefing.com

This submission was based on efficacy and safety data from Study 200, a single-arm
study of bosutinib in over 500 patients with previously treated Ph+ CML,
including patients resistant or intolerant to imatinib as well as patients who
were previously treated with dasatinib or nilotinib. Currently, there are no
approved therapies available for CML patients after second-line treatment with
dasatinib or nilotinib. Bosutinib is an oral, once-daily, investigational dual
Src and Abl kinase inhibitor with minimal inhibitory activity against c-kit and
PDGFR. It is believed that, by dual inhibition of the Src and Abl tyrosine
kinases, bosutinib may inhibit signaling in CML cells that allows the cells to
grow, survive and reproduce.

#2 cousineg


    New Member

  • Members
  • Pip
  • 3 posts

Posted 27 January 2012 - 11:26 AM

Another link about Bosutinib

1 user(s) are reading this topic

0 members, 1 guests, 0 anonymous users